Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Glioblastoma | Primary research

Nanos3, a cancer-germline gene, promotes cell proliferation, migration, chemoresistance, and invasion of human glioblastoma

Authors: Fengyu Zhang, Ruilai Liu, Cheng Liu, Haishi Zhang, Yuan Lu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Radiotherapy, chemotherapy, and surgery have made crucial strides in glioblastoma treatment, yet they often fail; thus, new treatment and new detection methods are needed. Aberrant expression of Nanos3 has been functionally associated with various cancers. Here, we sought to identify the clinical significance and potential mechanisms of Nanos3 in human glioblastoma.

Methods

Nanos3 expression was studied in nude mouse glioblastoma tissues and glioblastoma cell lines by immunohistochemistry, Western blot, and RT-PCR. Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing assay was performed to generate the Nanos3 knockdown glioblastoma cell lines. The effects of Nanos3 on glioblastoma cells proliferation, migration, invasion, chemoresistance, germ cell characteristics, and tumor formation were analyzed by CCK8, transwell, cell survival experiments and alkaline phosphatase staining in vitro and in nude mouse models in vivo. Correlation between the expression of stemness proteins and the expression of Nanos3 was evaluated by Western blot.

Results

We found that Nanos3 was strongly expressed in both glioblastoma cell lines and tissues. Western blot and sequencing assays showed that the Nanos3 knockdown glioblastoma cell lines were established successfully, and we discovered that Nanos3 deletion reduced the proliferation, migration, and invasion of glioblastoma cells in vitro (P < 0.05). Nanos3 knockdown enhanced the sensitivity of glioblastoma cells to doxorubicin (DOX) and temozolomide (TMZ) (P < 0.05), and Nanos3+/− glioblastoma cell lines did not show the characteristics of the germline cells. In addition, Nanos3 deletion inhibited subcutaneous xenograft tumor growth in vivo (P < 0.001). Moreover, the oncogenesis germline protein levels of CD133, Oct4, Ki67, and Dazl decreased significantly in glioblastoma cells following Nanos3 knockdown.

Conclusions

Both in vitro and in vivo assays suggest that Nanos3, which is a cancer-germline gene, initiates the tumorigenesis of glioblastoma via acquiring the oncogenesis germline traits. These data demonstrate that ectopic germline traits are necessary for glioblastoma growth.
Appendix
Available only for authorised users
Literature
1.
Zeng T, Cui D, Gao L. Glioma: an overview of current classifications, characteristics, molecular biology and target therapies. Front Biosci (Landmark Ed). 2015;1:1104–15.
2.
Le Rhun E, Taillibert S, Chamberlain MC. Anaplastic glioma: current treatment and management. Expert Rev Neurother. 2015;15(6):601–20.PubMedCrossRef
3.
Deluche E, Bessette B, Durand S, Caire F, Rigau V, Robert S, et al. CHI3L1, NTRK2, 1p/19q and IDH status predicts prognosis in glioma. Cancers. 2019;11(4):544.PubMedCentralCrossRef
4.
Kuo YC, Chang YH, Rajesh R. Targeted delivery of etoposide, carmustine and doxorubicin to human glioblastoma cells using methoxy poly(ethylene glycol)-poly(ε-caprolactone) nanoparticles conjugated with wheat germ agglutinin and folic acid. Mater Sci Eng C Mater Biol Appl. 2019;96:114–28.PubMedCrossRef
5.
López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, et al. Targeting glioma initiating cells with A combined therapy of cannabinoids and temozolomide. Biochem Pharmacol. 2018;157:266–74.PubMedCrossRef
6.
Munksgaard Thorén M, Chmielarska Masoumi K, Krona C, Huang X, Kundu S, Schmidt L, et al. Integrin α10, a novel therapeutic target in glioblastoma, regulates cell migration, proliferation, and survival. Cancers. 2019;11(4):587.PubMedCentralCrossRef
7.
Li XT, Li JC, Feng M, Zhou YX, Du ZW. Novel lncRNA-ZNF281 regulates cell growth, stemness and invasion of glioma stem-like U251s cells. Neoplasma. 2019;66(1):118–27.PubMedCrossRef
8.
Zhen Y, Nan Y, Guo S, Zhang L, Li G, Yue S, et al. Knockdown of NEAT1 repressed the malignant progression of glioma through sponging miR-107 and inhibiting CDK14. J Cell Physiol. 2019;234(7):10671–9.PubMedCrossRef
9.
Janic A, Mendizabal L, Llamazares S, Rossell D, Gonzalez C. Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Science. 2010;330(6012):1824–7.PubMedCrossRef
10.
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615–25.PubMedCrossRef
11.
Old LJ. Cancer vaccines: an overview. Cancer Immun. 2008;8(Suppl 1):1.PubMed
12.
Bonnomet A, Polette M, Strumane K, Gilles C, Dalstein V, Kileztky C, et al. The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression. Oncogene. 2008;27(26):3692–9.PubMedCrossRef
13.
Wang Z, Lin H. Nanos maintains germline stem cell self-renewal by preventing differentiation. Science. 2004;303(5666):2016–9.PubMedCrossRef
14.
15.
16.
Grelet S, Andries V, Polette M, Gilles C, Staes K, Martin AP, et al. The human NANOS3 gene contributes to lung tumour invasion by inducing epithelial–mesenchymal transition. J Pathol. 2015;237(1):25–37.PubMedCrossRef
17.
Tsuda M, Sasaoka Y, Kiso M, Abe K, Haraguchi S, Kobayashi S, et al. Conserved role of nanos proteins in germ cell development. Science. 2003;301(5637):1239–41.PubMedCrossRef
18.
Kusz KM, Tomczyk L, Sajek M, Spik A, Latos-Bielenska A, Jedrzejczak P, et al. The highly conserved NANOS2 protein: testis-specific expression and significance for the human male reproduction. Mol Hum Reprod. 2009;15(3):165–71.PubMedCrossRef
19.
Jørgensen A, Nielsen JE, Almstrup K, Toft BG, Petersen BL, Meyts ER-D. Dysregulation of the mitosis-meiosis switch in testicular carcinomain situ. J Pathol. 2013;229(4):588–98.PubMedCrossRef
20.
Miles WO, Korenjak M, Griffiths LM, Dyer MA, Provero P, Dyson NJ. Post-transcriptional gene expression control by NANOS is up-regulated and functionally important in pRb-deficient cells. EMBO J. 2014;33(19):2201–15.PubMedPubMedCentralCrossRef
21.
Safari M, Khoshnevisan A. Cancer stem cells and chemoresistance in glioblastoma multiform: a review article. J Stem Cells. 2015;10(4):271–85.PubMed
22.
Piccirillo SGM, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444(7120):761–5.PubMedCrossRef
23.
Pérez Castillo A, Aguilar-Morante D, Morales-García JA, Dorado J. Cancer stem cells and brain tumors. Clin Transl Oncol. 2008;10(5):262–7.PubMedCrossRef
24.
Cheng J-X, Liu B-L, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev. 2009;35(5):403–8.PubMedCrossRef
25.
Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell. 2008;13(1):69–80.PubMedPubMedCentralCrossRef
26.
Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127–34.PubMedCrossRef
27.
Sedaghat S, Gheytanchi E, Asgari M, Roudi R, Keymoosi H, Madjd Z. Expression of cancer stem cell markers OCT4 and CD133 in transitional cell carcinomas. Appl Immunohistochem Mol Morphol. 2017;25(3):196–202.PubMedCrossRef
28.
Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24(4):372–6.PubMedCrossRef
29.
Hattermann K, Flüh C, Engel D, Mehdorn HM, Synowitz M, Mentlein R, et al. Stem cell markers in glioma progression and recurrence. Int J Oncol. 2016;49(5):1899–910.PubMedCrossRef
30.
Du Y. The role and molecular mechanism of DAZL gene in lung cancer. Changsha: Hunan Normal University; 2019.
31.
Stefanidis K, Pergialiotis V, Christakis D, Patta J, Stefanidi D, Loutradis D. OCT-4 and DAZL expression in precancerous lesions of the human uterine cervix. J Obstet Gynaecol Res. 2015;41(5):763–7.PubMedCrossRef
32.
Stefanidis K, Loutradis D, Vassiliou L-V, Anastasiadou V, Kiapekou E, Nikas V, et al. Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells. Gynecol Oncol. 2008;111(2):344–9.PubMedCrossRef
33.
34.
35.
Zhang C, Yang M, Li Y, Tang S, Sun X. FOXA1 is upregulated in glioma and promotes proliferation as well as cell cycle through regulation of cyclin D1 expression. Cancer Manag Res. 2018;10:3283–93.PubMedPubMedCentralCrossRef
36.
Srikanth M, Kim J, Das S, Kessler JA. BMP signaling induces astrocytic differentiation of clinically derived oligodendroglioma propagating cells. Mol Cancer Res. 2014;12(2):283–94.PubMedCrossRef
37.
Klose A, Waerzeggers Y, Monfared P, Vukicevic S, Kaijzel EL, Winkeler A, et al. Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas. Neoplasia. 2011;13(3):276–85.PubMedPubMedCentralCrossRef
38.
Gomes WA, Mehler MF, Kessler JA. Transgenic overexpression of BMP4 increases astroglial and decreases oligodendroglial lineage commitment. Dev Biol. 2003;255(1):164–77.PubMedCrossRef
39.
Irish V, Lehmann R, Akam M. The Drosophila posterior-group gene nanos functions by repressing hunchback activity. Nature. 1989;338(6217):646–8.PubMedCrossRef
40.
Wang C, Lehmann R. Nanos is the localized posterior determinant in Drosophila. Cell. 1991;66(4):637–47.PubMedCrossRef
41.
Kobayashi S, Yamada M, Asaoka M, Kitamura T. Essential role of the posterior morphogen nanos for germline development in Drosophila. Nature. 1996;380(6576):708–11.PubMedCrossRef
42.
De Keuckelaere E, Hulpiau P, Saeys Y, Berx G, van Roy F. Nanos genes and their role in development and beyond. Cell Mol Life Sci. 2018;75(11):1929–46.PubMedCrossRef
43.
Wang J, Rousseaux S, Khochbin S. Sustaining cancer through addictive ectopic gene activation. Curr Opin Oncol. 2014;26(1):73–7.PubMedCrossRef
44.
Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science. 2015;350(6264):1096–101.PubMedPubMedCentralCrossRef
45.
Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown Kevin R, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163(6):1515–26.PubMedCrossRef
46.
Chen S, Sanjana Neville E, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160(6):1246–60.PubMedPubMedCentralCrossRef
47.
Han K, Jeng EE, Hess GT, Morgens DW, Li A, Bassik MC. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol. 2017;35(5):463–74.PubMedPubMedCentralCrossRef
48.
Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR–Cas9 screening of protein domains. Nat Biotechnol. 2015;33(6):661–7.PubMedPubMedCentralCrossRef
49.
Kurata M, Rathe SK, Bailey NJ, Aumann NK, Jones JM, Veldhuijzen GW, et al. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Sci Rep. 2016;6:36199.PubMedPubMedCentralCrossRef
50.
Strumane K, Bonnomet A, Stove C, Vandenbroucke R, Nawrocki-Raby B, Bruyneel E, Mareel M, et al. E-cadherin regulates human Nanos1, which interacts with p120ctn and induces tumor cell migration and invasion. Cancer Res. 2006;66(20):10007–15.PubMedCrossRef
51.
Loriot A, Boon T, De Smet C. Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int J Cancer. 2003;105(3):371–6.PubMedCrossRef
52.
Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5(186):186ra166.CrossRef
53.
Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, Herrmann IM, Graf D, et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain. 2010;133(7):1961–72.PubMedCrossRef
54.
55.
Tate CM, Pallini R, Ricci-Vitiani L, Dowless M, Shiyanova T, D’Alessandris GQ, Morgante L, et al. A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death Differ. 2012;19(10):1644–54.PubMedPubMedCentralCrossRef
56.
Voorneveld PW, Kodach LL, Jacobs RJ, van Noesel CJM, Peppelenbosch MP, Korkmaz KS, et al. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. Br J Cancer. 2015;112(1):122–30.PubMedCrossRef
57.
Metadata
Title
Nanos3, a cancer-germline gene, promotes cell proliferation, migration, chemoresistance, and invasion of human glioblastoma
Authors
Fengyu Zhang
Ruilai Liu
Cheng Liu
Haishi Zhang
Yuan Lu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01272-1

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Correction

Correction to: Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade

Primary research

SP1 induced long non-coding RNA LINC00958 overexpression facilitate cell proliferation, migration and invasion in lung adenocarcinoma via mediating miR-625-5p/CPSF7 axis

Primary research

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells

Primary research

Construction of a circRNA-miRNA-mRNA network based on competitive endogenous RNA reveals the function of circRNAs in osteosarcoma

Primary research

A methylation‐based mRNA signature predicts survival in patients with gastric cancer

Review

The emerging roles of non-coding competing endogenous RNA in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits